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Abstract  
Objectives 
Our first aim was to study the longitudinal changes of serum placental growth factor 
(PlGF) concentration between 12+0 to 28+0 weeks of gestation in the prospective 
PREDO cohort. Our second aim was to study the effect of low-dose acetylsalicylic acid 
(LDA; 100mg/day), started before the 14th week of gestation, on PlGF concentration.  
  
Study design 
Blood samples were collected at 12+0-14+0, 18+0-20+0 and 26+0-28+0 weeks of gestation 
in 101 women without and 309 with clinical risk factors for pre-eclampsia. Study cohort 
was divided into seven groups according to risk, treatment (no 
prevention/placebo/LDA) and outcome measure pre-eclampsia. Longitudinal changes 
in the PlGF concentration between groups were compared. To investigate the effect of 
LDA on serum PlGF concentration, placebo (N=62) and LDA (N=61) groups were 
compared. A repeated measures ANOVA was used to analyze differences in PlGF 
levels between the groups.  
Results 
The increase in serum PlGF concentration was higher in LDA than in placebo group 
(time×group effect, p=0.046). The increase in serum PlGF concentration during 
pregnancy was lower in risk-women who developed pre-eclampsia and in high-risk 
women who had placebo and developed pre-eclampsia compared to the other women 
(time×group effect, p<0.001). There were no differences in PlGF change between low-
risk women, risk-women who did not develop pre-eclampsia, high-risk women in the 
placebo group without pre-eclampsia and high-risk women in the LDA group with and 
without pre-eclampsia (p=0.15).  
Conclusions 
Our finding suggests an association between LDA started before 14 weeks of 








PlGF = placental growth factor, LDA = low-dose acetylsalicylic acid, Uta-PI = uterine 
artery pulsatility index, ANOVA = one-way analyses of variance, BMI = body mass 
index, MAP = mean arterial pressure, mmHg = millimeter of mercury  
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Pre-eclampsia is a hypertensive pregnancy disorder that affects 2-8% of 
pregnant women. It is a major cause of maternal and fetal morbidity and mortality [1, 
2]. Blood concentration of placental growth factor (PlGF) is lower already in the early 
pregnancy in women who will later develop pre-eclampsia [3, 4] and therefore it is a 
  
promising biomarker, especially for early-onset pre-eclampsia and when combined 
with other biomarkers and biophysical measurements [5-7]. Low-dose acetylsalicylic 
acid (LDA) started at 12-16 weeks of gestation reduces the risk of pre-eclampsia [8-
10]. Our aim was to study maternal serum PlGF concentration in a prospective cohort 
of women with clinical risk factors for pre-eclampsia and of low-risk control women, 





The present study is a part of the multidisciplinary ‘Prediction and Prevention of Pre-
eclampsia and Intrauterine Growth Restriction’ (PREDO) Project [11]. The study cohort 
was collected prospectively between September 2005 and December 2009 in ten 
participating hospital maternity clinics in Finland. The inclusion and exclusion criteria 
are listed in Supplementary Table 1 and the flow chart of the study is presented in 
Supplementary Figure 1. Originally 1082 women were recruited, 972 women that 
fulfilled the inclusion criteria, which had predetermined risk factors for pre-eclampsia, 
and 110 randomly selected women without known risk factors for pre-eclampsia as a 
low-risk reference group. All participants had first trimester visit at 12+0-14+0 weeks of 
gestation. The bilateral waveform of uterine artery blood flow was determined and 
uterine artery pulsatility index (Uta-PI) was measured with Doppler ultrasound 
examination. Fasting blood sample was collected. During the study period, a total of 
45 (4.2%) recruited women were later excluded for various reasons [10].  
Of 972 women with risk factors for pre-eclampsia (inclusion criteria in 
Supplementary Table 1) 142 were randomized to a placebo controlled LDA-trial [10]. 
  
The inclusion criterion to the LDA-trial was bilateral second-degree diastolic notch in 
the uterine artery Doppler ultrasound, as a reflection of increased resistance to blood 
flow and therefore, higher risk, performed at the first visit. All women participating in 
the LDA-trial were included in this substudy and were defined as high-risk. Reference 
groups composed of 202 women with risk factors and without bilateral second-degree 
notch and 110 women without known risk factors for pre-eclampsia. All gave blood 
samples in three time points of pregnancy: at 12+0 to 14+0, 18+0 to 20+0 and 26+0 to 28+0 
weeks of gestation. Blood samples were drawn from antecubital vein and serum was 
separated within an hour by centrifugation and stored in -80°C until analysis. Serum 
PlGF concentration was measured with AutoDelfia analyzer (Wallac, PerkinElmer, 
Turku, Finland). 
Primary outcome was pre-eclampsia, defined as a systolic blood pressure ≥140 
mmHg and/or a diastolic blood pressure ≥ 90 mmHg occurring after 20 weeks of 
gestation in a woman with previously normal blood pressure combined with a urinary 
24-hour protein excretion of ≥ 0.3 g or the dipstick equivalent in two consecutive 
measurements [12]. Pre-eclampsia superimposed on chronic hypertension were 
included in the primary outcome. Secondary outcomes were early-onset pre-eclampsia 
(diagnosed before 34+0 weeks of gestation) and severe pre-eclampsia (systolic blood 
pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 110 mmHg and/or proteinuria 
≥ 5 g/24 hours). All diagnoses were independently confirmed by a jury of two 
physicians and one research nurse, as earlier described [10]. Ethics Committee of the 
Helsinki and Uusimaa Hospital District approved the study and written informed 
consent was obtained from all participants. 
To study the changes in serum PlGF concentration in longitudinal samples 
according to outcome measure pre-eclampsia, the cohort was divided in 7 subgroups 
  
as follows: group 1: low-risk women (no known risk factors) (N=101), group 2: risk-
women (=risk factors but no bilateral second-degree diastolic notch) who did not 
develop pre-eclampsia (N=163), group 3: risk-women (=risk factors but no bilateral 
second-degree diastolic notch) who developed pre-eclampsia (N=23), group 4: high-
risk women (=bilateral second-degree diastolic notch; LDA-trial participants) who had 
placebo treatment and did not develop pre-eclampsia (N=51), group 5: high-risk 
women (=bilateral second-degree diastolic notch; LDA-trial participants) who had 
placebo treatment and developed pre-eclampsia (N=11), group 6: high-risk women 
(=bilateral second-degree diastolic notch; LDA-trial participants) who had LDA 
treatment and did not develop pre-eclampsia (N=55) and group 7: high-risk women 
(=bilateral second-degree diastolic notch; LDA-trial participants)  who had LDA 
treatment and developed pre-eclampsia (N=6) (Supplementary Figure 1).  
To investigate the effect of LDA on PlGF concentration and changes in PlGF 
concentration in the longitudinal samples we compared the high-risk women who were 
randomized to the placebo group (n=62) (groups 4 and 5) or to LDA (n=61) group 




The difference of means in normally distributed baseline variables between 
groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s 
post-hoc tests. Kruskal-Wallis test was used in case the data was not normally 
distributed. Comparison of medians of different non-normally distributed variables was 
done with Mann-Whitney U test. Bonferroni corrections were used in post-hoc 
comparisons. Categorical variables were compared with chi-square test. 
  
 The repeated measures analysis of variance (ANOVA) was used to 
analyze differences in serum PlGF levels between the groups. The model included the 
main effects of time, group and the interaction effect time×group. Log-transformed 
PlGF values were used in these analyses due to the positively skewed distribution. 
The comparisons between LDA and placebo groups were adjusted for pre-pregnancy 
body mass index (BMI), chronic hypertension and first trimester mean arterial pressure 
(MAP). Results of PIGF values are expressed as geometric means (95% confidence 
intervals). In all analyses p-value < 0.05 was considered statistically significant. 





Clinical characteristics of all study groups are presented in Supplementary 
Table 2 and pregnancy characteristics in Supplementary Table 3. There were 30 pre-
eclampsia cases (7.3%), 10 (2.4%) women had early-onset pre-eclampsia, and 17 
(4.1%) had severe form of the disease.  
The geometric means of PlGF concentration in each group are presented in 
Table 1. Change in PlGF concentration was lower in risk-women who developed pre-
eclampsia (Group 3) and in high-risk women who had placebo treatment and 
developed pre-eclampsia (Group 5) compared to all other groups (p<0.001) (Figure 1 
and Table 2). The change in PlGF concentration between the other groups did not 
differ in three different time points during pregnancy (p=0.15) (Figure 1 and Table 2). 
 Clinical characteristics of three risk-women groups (risk-women, placebo and 
LDA) are presented in Supplementary Table 4 and pregnancy characteristics in 
  
Supplementary Table 5.  Women in placebo and LDA groups had second-degree 
bilateral diastolic notch in the uterine artery flow and they had the highest mean Uta-PI 
in early pregnancy compared to the rest of the study cohort.  
The adjusted geometric means of PlGF concentration and longitudinal changes 
in the PlGF concentration between LDA and placebo groups are presented in Table 3 
and Table 4, Figure 2. After adjustment for BMI, chronic hypertension and MAP, the 
change in PlGF concentration was lower in the placebo group than in the LDA group 
(interaction effect time×group, p=0.046), particularly change between sample 2 (18+0-
20+0 weeks of gestation) and 3 (26+0-28+0 weeks of gestation) differed in further 
analysis (placebo 104.9 ηg/ml vs. LDA 174.5 ηg/ml, interaction effect time×group, 
p=0.043). When pre-eclampsia was added as a covariant into the repeated 
measurements model, it did not change the result regarding the effect of LDA on 
serum PlGF concentration (interaction effect time×group, p=0.046 vs. p=0.047).  
 
Conclusion and discussion 
 
To our best knowledge, this is the first study to show the association between 
LDA started before 14 weeks of gestation and higher increase in serum PlGF 
concentration in women with high-risk for pre-eclampsia during pregnancy. 
The strength of our study is a carefully characterized prospective cohort, 
wherein all diagnoses were confirmed from hospital records by a jury of two physicians 
and a study nurse. The effect of LDA on serum PlGF concentrations was studied in 
prospective high-risk cohort with double-blinded placebo controlled study design. 
However, the sample size was relatively small. Therefore, these findings need to be 
confirmed in a larger prospective cohort of pregnant women.  
  
 The cause of pre-eclampsia is unknown, but there is strong evidence that 
impaired placentation is one pathophysiological mechanism [13] and more associated 
with early-onset and severe pre-eclampsia [14, 15] . PlGF is a member of vascular 
growth factor family and secreted predominantly by the trophoblasts during pregnancy. 
The exact role of PlGF in pregnancy is not known, but it seems to be involved in 
placental growth and differentiation [16] and with an other pro-angiogenic factor, 
vascular endothelial growth factor (VEGF) and their anti-angiogenic counterpart, 
soluble fms-like tyrosine kinase-1 (sFlt-1), forms a complicated system that maintains 
normal endothelial structure and function [17, 18].  
In screening population median serum PlGF concentration has a curvilinear 
relationship with gestational age. Maternal serum PlGF concentration increases in the 
first and second trimester, reaching a maximum level at around 30 weeks and 
subsequently decreases [19]. Women who develop pre-eclampsia have lower serum 
PlGF concentration already in the early pregnancy compared to women with normal 
pregnancies [20] although this difference becomes more clear with advancing 
pregnancy [3, 21, 22]. Low PlGF concentration is thought to reflect abnormal placental 
angiogenesis [23]. The timing and the site of the abnormal placentation may contribute 
to the pregnancy outcome [24].  
In the present study the increase in PlGF concentration was lower in the risk-
women with pre-eclampsia without any treatment and in high-risk women who 
developed pre-eclampsia in the placebo group compared to the other groups. This is 
in accordance with earlier studies, in which serum or plasma levels of PlGF are 
reduced in pregnancies complicated by pre-eclampsia [3, 4], especially in the early-
onset disease [21].  
  
Bilateral high resistance indices (PI and resistance index) of the uterine arteries 
are also associated with impairment in placentation [25, 26]. High-risk women in the 
placebo group who developed pre-eclampsia had higher Uta-PI than risk-women who 
developed pre-eclampsia (p=0.001) already at the recruitment due to the inclusion 
criteria (bilateral second-degree diastolic notch in Doppler ultrasound examination of 
uterine artery flow) of the LDA-trial. Altogether, lower serum PlGF levels and higher 
Uta-PI of high-risk women with pre-eclampsia in placebo group, compared with risk-
women with pre-eclampsia, probably were due to more earlier or profound impairment 
of placentation of high-risk women in placebo group with pre-eclampsia than in risk-
women with pre-eclampsia [24].  
Increasing evidence suggests that LDA treatment during pregnancy reduces the 
risk of developing pre-eclampsia [27, 28]. However, there is still ongoing debate over 
the timing and dose of LDA treatment [29]. A recent prospective, double-blinded 
placebo-controlled study on women with high risk for pre-eclampsia showed clear 
evidence, that LDA 150mg per day started at 11-14 weeks of gestation reduces the 
risk of developing preterm pre-eclampsia resulting in delivery before 37 weeks of 
gestation and early-onset pre-eclampsia (delivery before 34 weeks of gestation) even 
more efficiently [30].  
It has been suggested that LDA facilitates early placental embedding and acts 
as a vasodilator by increasing prostacyclin production. LDA may also have direct effect 
on platelets or it may decrease endothelial dysfunction by other mechanisms [29]. It 
may have indirect effect on PlGF concentration by dose-dependently inhibiting sFlt-1 
production in cytotrophoblasts via cyclo-oxygenase-1 inhibition [31].  Recently, 
Panagodage et al. showed in an in vitro model of early-onset pre-eclampsia, that LDA 
modulates the production of cytokines and improves trophoblast function. By that 
  
means LDA may increase trophoblast secretion of PlGF. LDA may also restore 
abnormal production of cytokines by trophoblasts, induced by pre-eclampsia serum, to 
levels observed in normotensive serum, and may, as well, attenuate abnormal 
trophoblast apoptosis and growth caused by pre-eclampsia serum [32]. This could 
mean that lower increase of serum PlGF levels, more evident from second trimester 
onward in pre-eclampsia pregnancies, reflects abnormal trophoblast function, and is 
partly reversible by LDA treatment. In the present study the effect of LDA on serum 
PlGF levels was evident from mid-gestation onward. This provides a further rationale 
to arguments that LDA treatment should be continued to the late third trimester.  
 This is the first study to show association between daily LDA started before 14 
weeks of gestation and higher longitudinal increase in serum PlGF concentration in 
high-risk women during pregnancy. This finding may also be associated with the 
reduced risk of developing pre-eclampsia in high-risk women. 
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Table 1. The geometric means of serum PlGF levels of study groups in three different sampling points during pregnancy. 
Weeks of Gestation/  12-14 95% CI  18-20 95% CI 26-28 95% CI 
PlGF concentration
a
 ηg/ml Lower Upper ηg/ml Lower Upper ηg/ml Lower Upper 
Low-risk women (Group 1) 24.9 23.3 26.7 120.5 109.3 132.9 322.2 287.5 361.1 
Risk-women, no PE (Group 2) 24.6 23.0 26.3 111.5 103.4 120.2 299.4 269.1 333.1 
Risk-women, PE (Group 3) 23.7 19.8 28.3 108.5 87.5 134.4 133.8 91.6 195.3 
Placebo, no PE (Group 4) 21.9 19.9 24.0 100.2 85.9 116.9 228.8 185.1 282.9 
Placebo, PE (Group 5) 20.0 15.8 25.4 62.3 30.3 128.1 75.9 27.1 212.2 
LDA, no PE (Group 6) 22.4 20.4 24.6 109.2 93.4 127.6 267.9 224.6 319.6 
LDA, PE (Group 7) 28.0 22.0 35.6 93.7 51.6 170.1 220.8 125.6 388.2 
a geometric means 
         PlGF=placental growth factor, PE=pre-eclampsia, CI=confidence interval, LDA= low-dose acetylsalicylic acid (100mg/day) 
  
Table 2. The change of serum PlGF concentration from 12-14 weeks of gestation to 18-20 weeks of 









Lower Upper Lower Upper 
Low-risk women (Group 1) 95.6 86.0 106.2 201.6 178.2 228.2 
Risk-women, no PE (Group 2) 86.9 80.4 94.0 187.9 165.6 212.9 
Risk-women, PE (Group 3) 84.7 67.7 106.1 25.3 4.1 60.9 
Placebo, no PE (Group 4) 78.4 66.0 93.0 128.5 99.1 166.0 
Placebo, PE (Group 5) 42.3 14.5 102.8 13.6 -3.1 84.1 
LDA, no PE (Group 6) 86.7 73.0 103.0 158.7 131.3 192.0 
LDA, PE (Group 7) 65.7 29.6 134.5 127.1 74.0 218.1 
a calculated from geometric means 
PlGF=placental growth factor, PE=pre-eclampsia, CI=confidence interval, LDA= low-dose acetylsalicylic acid (100mg/day) 
The change in serum PlGF concentrations was lower in Group 3 and Group 5 compared to Groups 1, 2, 4, 6 and 7 
(interaction effect time×group, p<0.001). 
 
Table 3. The adjusted geometric means of serum PlGF levels of the study groups in three different 
sampling points during pregnancy. 
Weeks of Gestation/  12-14 95% CI 18-20 95% CI  26-28 95% CI 
PlGF concentration
a
 ηg/ml Lower Upper ηg/ml Lower Upper ηg/ml Lower Upper 
Placebo 23.5 20.6 26.8 94.2 80.0 110.9 199.1 161.1 245.5 
LDA 24.3 21.2 27.9 113.2 95.7 134.0 287.7 232.3 357.3 
Risk-women 27.2 25.2 29.4 123.3 112.2 135.8 305.5 269.8 345.9 
a geometric mean 










Table 4. The change of adjusted geometric mean serum PlGF concentration from 12-
14 weeks of gestation to 18-20 weeks of gestation (ΔPlGF12) and from 18-20 weeks 










Lower Upper Lower Upper 
Placebo 70.7 59.4 84.1 104.9 81.1 134.6 
LDA 89.0 74.5 106.1 174.5 136.6 223.3 
Risk-women 96.1 87.0 106.5 182.2 157.6 210.1 
a calculated from geometric means 
PlGF=placental growth factor, PE=pre-eclampsia, CI=confidence interval, LDA= low-dose 
acetylsalicylic acid (100 mg/day) 
 
After adjustment for BMI, chronic hypertension and MAP, the change in PlGF concentration was lower in placebo 
group than in LDA group (interaction time×group, p=0.046), particularly change between sample 2 and 3 differed 


















 This study shows an association between low-dose aspirin (100mg/d) started in 
early pregnancy and increase in serum placental growth factor levels (PlGF). 
 The effect of aspirin on PlGF levels is seen after mid-gestation. 
 This finding may be related to the reduced risk of developing pre-eclampsia. 
 
